A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells | Zendy

Matthew Mahoney | Zendy; Vishnu C. Damalanka | Zendy; Michael A. Tartell | Zendy; Dong hee Chung | Zendy; André Luiz Lourenço | Zendy; Dustin Pwee | Zendy; Anne E. Mayer Bridwell | Zendy; Markus Hoffmann | Zendy; Jorine Voss | Zendy; Partha Karmakar | Zendy; Nurit P. Azouz | Zendy; Andrea M. Klingler | Zendy; Paul W. Rothlauf | Zendy; Cassandra E. Thompson | Zendy; Melody Lee | Zendy; Lidija Klampfer | Zendy; Christina L. Stallings | Zendy; Marc E. Rothenberg | Zendy; Stefan Pöhlmann | Zendy; Sean P. J. Whelan | Zendy; Anthony J. O’Donoghue | Zendy; Charles S. Craik | Zendy; James W. Janetka | Zendy

Open Access

A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells

Author(s) -

Matthew Mahoney,

Vishnu C. Damalanka,

Michael A. Tartell,

Dong hee Chung,

André Luiz Lourenço,

Dustin Pwee,

Anne E. Mayer Bridwell,

Markus Hoffmann,

Jorine Voss,

Partha Karmakar,

Nurit P. Azouz,

Andrea M. Klingler,

Paul W. Rothlauf,

Cassandra E. Thompson,

Melody Lee,

Lidija Klampfer,

Christina L. Stallings,

Marc E. Rothenberg,

Stefan Pöhlmann,

Sean P. J. Whelan,

Anthony J. O’Donoghue,

Charles S. Craik,

James W. Janetka

Publication year - 2021

Publication title -

proceedings of the national academy of sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.011

H-Index - 771

eISSN - 1091-6490

pISSN - 0027-8424

DOI - 10.1073/pnas.2108728118

Subject(s) - tmprss2 , virology , serine protease , ex vivo , coronavirus , virus , proteases , in vivo , viral entry , protease , protease inhibitor (pharmacology) , cytopathic effect , biology , viral replication , viral load , covid-19 , medicine , enzyme , biochemistry , microbiology and biotechnology , disease , pathology , antiretroviral therapy , infectious disease (medical specialty)

Significance MM3122 represents an advanced lead candidate for clinical development as a novel antiviral drug for COVID-19. In addition to being novel drugs, these selective TMRSS2 inhibitors can be used as valuable chemical probes to help elucidate mechanisms of viral pathogenesis. Since TMPRSS2 plays a key role as a viral protein processing protease in the pathogenesis of other coronaviruses (SARS-CoV, MERS-CoV) as well as influenza viruses, MM3122 and this class of TMPRSS2 inhibitors hold much promise as new drugs to not only treat SARS-CoV-2 infections but also potentially represent broad-spectrum antivirals.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research